T
Tim Magnus
Researcher at University of Hamburg
Publications - 154
Citations - 7001
Tim Magnus is an academic researcher from University of Hamburg. The author has contributed to research in topics: Microglia & Inflammation. The author has an hindex of 38, co-authored 133 publications receiving 5338 citations. Previous affiliations of Tim Magnus include Hamburg University of Technology & Eppendorf (Germany).
Papers
More filters
Journal ArticleDOI
CD38 exacerbates focal cytokine production, postischemic inflammation and brain injury after focal cerebral ischemia.
Chi-Un Choe,Kerstin Lardong,Mathias Gelderblom,Peter Ludewig,Frank Leypoldt,Friedrich Koch-Nolte,Christian Gerloff,Tim Magnus +7 more
TL;DR: CD38 is differentially regulated following stroke and its deficiency attenuates the postischemic chemokine production, the immune cell infiltration and the cerebral injury after temporary ischemia and reperfusion, and might prove a therapeutic target in ischemic stroke.
Journal ArticleDOI
Autoimmunity After Ischemic Stroke and Brain Injury.
Ehsan Javidi,Tim Magnus +1 more
TL;DR: The role of autoimmunity in post-lesional conditions is summarized and the role of B and T cells and their potential neuroprotective or detrimental effects are discussed.
Journal ArticleDOI
Calorie restriction and stroke
TL;DR: The protective mechanisms activated by dietary energy restriction in ischemic stroke are discussed, including activation of glial cells and infiltration of leukocytes, and anti-inflammatory cytokines.
Journal ArticleDOI
Dendritic cells in brain diseases.
Peter Ludewig,Mattia Gallizioli,Xabier Urra,Sarah Behr,Vanessa H Brait,Mathias Gelderblom,Tim Magnus,Anna M. Planas +7 more
TL;DR: Dendritic cells are professional antigen presenting cells that constantly survey the environment acting as sentinels of the immune system, including in the CNS, and the literature reporting DCs in the inflamed brain in disease conditions and corresponding animal models is reviewed.
Journal ArticleDOI
Functional Outcome of Intravenous Thrombolysis in Patients With Lacunar Infarcts in the WAKE-UP Trial
Ewgenia Barow,Florent Boutitie,Florent Boutitie,Bastian Cheng,Tae-Hee Cho,Martin Ebinger,Martin Ebinger,Matthias Endres,Jochen B. Fiebach,Jens Fiehler,Ian Ford,Ivana Galinovic,Alina Nickel,Josep Puig,Pascal Roy,Anke Wouters,Anke Wouters,Tim Magnus,Vincent Thijs,Robin Lemmens,Robin Lemmens,Keith W. Muir,Norbert Nighoghossian,Salvador Pedraza,Claus Z Simonsen,Christian Gerloff,Götz Thomalla +26 more
TL;DR: The WAKE-UP trial was not powered to demonstrate the efficacy of treatment in subgroups of patients, but results indicate that the association of intravenous alteplase with functional outcome does not differ in patients with imaging-defined lacunar infarcts compared with those experiencing other stroke subtypes.